| 2026-08-06 | Press release | Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer |
| 2026-07-28 | Press release | Agenus to Provide Second Quarter 2026 Financial Report and Development Update |
| 2026-07-17 | Press release | Download , Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advance |
| 2026-07-17 | Press release | Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas |
| 2026-07-13 | Press release | Download , Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Tria |
| 2026-07-13 | Press release | Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadj |
| 2026-07-12 | Presentation | Download PDF file, (opens in new window) |
| 2026-07-12 | Presentation | Webcast Presentation Open Event Link, PDF file, July 13, 2026, (opens in new window) |
| 2026-07-06 | Press release | Download , Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Col |
| 2026-07-06 | Press release | Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Can |
| 2026-06-25 | Press release | Download , Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to |
| 2026-06-25 | Press release | Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presente |
| 2026-06-16 | Press release | Agenus Announces Virtual 2026 Annual Shareholders Meeting |
| 2026-06-02 | Press release | Download , Agenus Announces Virtual 2026 Annual Shareholders Meeting, June 2, 2026, (opens in new window) |
| 2026-05-31 | Press release | Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-R |
| 2026-05-21 | Press release | Download , Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced C |
| 2026-05-21 | Press release | Download , Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images t |
| 2026-05-15 | Press release | Download , Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellul |
| 2026-05-15 | Press release | Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinom |
| 2026-05-11 | Press release | Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 De |
| 2026-05-11 | Press release | Agenus to Provide First Quarter 2026 Financial Report and Corporate Update |
| 2026-05-04 | Press release | Download , Agenus to Provide First Quarter 2026 Financial Report and Corporate Update, May 4, 2026, (opens in new window |
| 2026-04-21 | Press release | Download , Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026, April 21, 2026 |
| 2026-04-21 | Press release | Download , Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs, April 21, 2026, (opens in ne |
| 2026-04-17 | Press release | Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and |
| 2026-04-03 | Press release | Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal C |
| 2026-04-01 | Press release | Download , Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination |
| 2026-03-26 | Press release | Download , Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor |
| 2026-03-17 | Press release | Download , Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS M |
| 2026-03-16 | Press release | Download , Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initi |
| 2026-03-10 | Press release | Download , Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manu |
| 2026-03-04 | Press release | Download , Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update, March 4, 2026, (ope |
| 2026-02-19 | Press release | Download , Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Co |
| 2026-02-09 | Press release | Download , Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Im |
| 2026-01-21 | Press release | Download , Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access |
| 2026-01-20 | Press release | Agenus to Host First 2026 Stakeholder Webcast |
| 2026-01-15 | Press release | Download , Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Stre |
| 2026-01-12 | Press release | France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas |
| 2025-03-11 | Press release | Press Release of Q4 2024 Report, (opens in new window) |
| 2024-11-12 | Press release | Q3 (opens in new window) |